Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review
Authors:
- An.DRew HillAHAn.DRew Hill
Open Access
- 1 April 2018
- journal article
- review article
- Published by Elsevier in Journal of Virus Eradication
- Vol. 4 (2) , 66-71
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Integrase inhibitors in late pregnancy and rapid HIV viral load reductionAmerican Journal of Obstetrics and Gynecology, 2016
- Brief ReportJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1AIDS, 2015
- Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion modelJournal of Antimicrobial Chemotherapy, 2015
- Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIVDrug Design, Development and Therapy, 2015
- Pharmacokinetics of Dolutegravir in a Premature Neonate after HIV Treatment Intensification during PregnancyAntimicrobial Agents and Chemotherapy, 2015
- Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and ZambiaAIDS, 2014
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyThe Lancet, 2014
- Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in BotswanaThe Journal of Infectious Diseases, 2012
- Pregnancy loss and role of infant HIV status on perinatal mortality among HIV-infected womenBMC Pediatrics, 2012